Novo Nordisk launches Levemir FlexTouch insulin delivery device in US

18 June 2014 (Last Updated June 18th, 2014 18:30)

Novo Nordisk has announced the launch of its Levemir (insulin detemir [rDNA origin] injection) FlexTouch insulin delivery device in the US.

Image

Novo Nordisk has announced the launch of its Levemir (insulin detemir [rDNA origin] injection) FlexTouch insulin delivery device in the US.

Levemir FlexTouch is a prefilled insulin pen containing 300 units of insulin detemir. The insulin delivery device is compatible with both NovoFine and the latest NovoTwist needles. It doses in one-unit increments up to 80 units.

The Levemir FlexTouch device features a push-button that does not extend at any set dose and allows insulin to be administered by pressing the low injection force button.

"The Levemir FlexTouch device features a push-button that does not extend at any set dose and allows insulin to be administered by pressing the low injection force button."

Novo Nordisk obtained approval from the US Food and Drug Administration for FlexTouch in November 2013 and the European Medicines Agency's approval in July 2011.

The company has launched its latest insulin delivery device in several countries, including the UK, Canada, Denmark, and Japan.

Novo Nordisk diabetes marketing senior vice-president Camille Lee said the company is developing devices to help more than 29 million people with diabetes in the US.

"Levemir FlexTouch was designed to address the needs of these individuals, providing patients and their health care professionals with a new tool to help improve the way they manage their diabetes," Lee said.

Levemir is a manufactured long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus. The company claims that the Levemir FlexTouch insulin delivery device advancement represents advancement in the basal insulin category.


Image: Novo Nordisk's FlexTouch insulin delivery device. Photo: courtesy of Novo Nordisk A/S.